This application renews a Research Scientist Award to enable Dr. Kosten to continue to pursue full time research and to train new researchers in the pharmacotherapy of cocaine and opioid dependence. During the last 5 years, Dr. Kosten has published over 100 articles, been a mentor for 5 junior faculty and 5 fellows, participated extensively in research reviews, and provided national and international consultations on pharmacotherapy. His broader roles include leadership in national organizations such as Presidency of the American Academy of Addiction Psychiatry and dissemination of buprenorphine treatment for opiate dependence through national education programs and leadership in the New England Clinical Trials Network. During the proposed award period, Dr. Kosten will continue mentoring and training activities and pursue two research goals. Goal 1 is to develop innovative cocaine pharmacotherapies (FDA Phase 1), conduct randomized clinical trials of them (FDA Phase 2), and develop new biomarkers of treatment response. Goal 2 is to use biological markers, such as genetic polymorphisms, to improve prediction of pharmacotherapy outcome and potentially match patients to the most effective treatment. His new NIDA Center (P50-DA18197) supports Goal 1 with a human laboratory for phase 1 testing of pharmacotherapies that currently include GABA agonists, and by 2006 will include a highly specific dopamine reuptake inhibitor (RTI 336) and a monoclonal antibody. Funded Phase 2 trials include: a cocaine vaccine, bupropion with contingency management, and 2 Center funded studies. A detailed Research Plan is provided for the cocaine vaccine study. This 20 week, randomized placebo-controlled, double blind clinical trial vaccinates 120 patients maintained on methadone for comorbid opioid and cocaine dependence. The Center's Phase 2 studies also address Goal 2 to examine pharmacogenetics of cocaine abuse treatment response. One study relates a functional polymorphism of dopamine beta hydroxylase to disulfiram response. Another study relates polymorphisms of GABA receptors and metabolism to treatment response with GABA agents, and a third relates the short/long promoter polymorphism of the serotonin transporter to treatment response with serotonin reuptake inhibitors. Coupled to these research goals are mentoring of junior researchers and the dissemination of information on new treatment approaches to addiction.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Scientist Award (K05)
Project #
Application #
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Biswas, Jamie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code
Bashiri, Maryam; Mancino, Michael J; Stanick, Virginia A et al. (2017) Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict 26:807-814
Shorter, Daryl; Hsieh, John; Kosten, Thomas R (2015) Pharmacologic management of comorbid post-traumatic stress disorder and addictions. Am J Addict 24:705-12
Zhang, Xiang Y; Chen, Da C; Xiu, Mei H et al. (2014) Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls. Schizophr Bull 40:592-601
Zhang, Xiang Yang; Chen, Da Chun; Tan, Yun Long et al. (2014) Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population. Psychopharmacology (Berl) 231:305-14
Mancino, Michael J; McGaugh, Janette; Chopra, Mohit P et al. (2014) Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 34:234-9
Kosten, Thomas; Domingo, Coreen; Orson, Frank et al. (2014) Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol 77:368-74
Schottenfeld, Richard S; Chawarski, Marek C; Cubells, Joseph F et al. (2014) Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 136:36-42
Zhang, Xiang Yang; Al Jurdi, Rayan K; Zoghbi, Anthony William et al. (2013) Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia. J Psychiatr Res 47:1370-5
Zhen, Yan Feng; Zhang, Jia; Liu, Xing Yu et al. (2013) Low BDNF is associated with cognitive deficits in patients with type 2 diabetes. Psychopharmacology (Berl) 227:93-100
Wu, Jing Qin; Chen, Da Chun; Xiu, Mei Hong et al. (2013) Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 46:71-7

Showing the most recent 10 out of 150 publications